Age-related learning and memory decline in the brain has also been shown to be accompanied by inflammatory changes, typified by microglial activation. These changes are also accompanied and possibly triggered by an increase in pro-inflammatory cytokines and a decrease in protective cytokines.
Amarin is currently developing Miraxion in phase III clinical trials for Huntington’s disease and has completed several phase II trials in depressive disorders.
The research was carried out by Amarin in collaboration with the Institute of Neuroscience at Trinity College, Dublin.
“Our long term commitment to neurology research has resulted in these important findings. Determining how Miraxion actually functions in the brain and establishing that Miraxion has neuroprotective effects is fundamental to our understanding of its mechanism of action in neurodegenerative diseases and depressive disorders,” said Rick Stewart, CEO of Amarin.